Evidence map›Paper›PMID 40063243›Full record

Trial reportAnnals of hematology2025

Gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia: a regional analysis of COMMODORE in China, South-East Asia, and Russia.

Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Xiaoxi Zeng, Taishi Sakatani, Masanori Kosako, Yaru Deng and 7 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bin JiangDepartment of Hematology, Peking University International Hospital, Beijing, China.
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China.
Ligen LiuDepartment of Hematology, Tongren Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xin DuDepartment of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China.
Hao JiangDepartment of Hematology, Peking University People's Hospital, Beijing, China.
Jianda HuFujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Xiaoxi ZengAstellas China Investment Co, Ltd., Beijing, China.
Taishi SakataniAstellas Pharma, Inc., Tokyo, Japan.
Masanori KosakoAstellas Pharma, Inc., Tokyo, Japan.ORCID https://orcid.org/0000-0002-4981-9450
Yaru DengAstellas China Investment Co, Ltd., Beijing, China.
Larisa GirshovaPersonalized Medicine Center, Almazov National Medical Research Center, St. Petersburg, Russia.
Sergey BondarenkoDepartment of Bone Marrow Transplantation of Adults, RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia.
Lily Wong Lee LeeDepartment of Hematology, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia.
Archrob KhuhapinantDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Elena MartynovaDepartment of Hematology and Chemotherapy, Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russia.
Nahla HasabouAstellas Pharma, Inc., Northbrook, IL, USA.
Jianxiang WangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. wangjx@ihcams.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COMMODORE study demonstrated the efficacy and safety of gilteritinib versus salvage chemotherapy (SC) treatment in a predominantly Asian population with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated(

Indexed as

Aniline Compoundsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationPyrazinesSalvage TherapyAdolescentAdultAgedAsia, SoutheasternChinaEast Asian PeopleEastern European PeopleFemaleHumansMaleAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPyrazines

Identifiers

PMID40063243
PMCPMC12031924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.